PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS TREATMENT MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: BYR-138769 | Medical Devices
Historical data: 2017 - 2023
Forecast period: 2025 - 2031
Quantitative units: Revenue in USD million and CAGR from 2025 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Primary Progressive Multiple Sclerosis Treatment Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS TREATMENT MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS TREATMENT MARKET
7.1 GLOBAL PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS TREATMENT MARKET SIZE AND SHARE (2017 - 2031) (USD MILLION)
8.1 GLOBAL PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS TREATMENT MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
8.2 GLOBAL PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS TREATMENT MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
9.1 GLOBAL PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
9.2 GLOBAL PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
10.1 GLOBAL PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS TREATMENT MARKET SIZE AND SHARE BY REGION (2017 - 2023) (USD MILLION)
10.2 GLOBAL PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS TREATMENT MARKET SIZE AND SHARE BY REGION (2025 - 2031) (USD MILLION)
11.1 NORTH AMERICA PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
11.2 NORTH AMERICA PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
11.3 NORTH AMERICA PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS TREATMENT MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
11.4 NORTH AMERICA PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS TREATMENT MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
11.5 NORTH AMERICA PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
11.6 NORTH AMERICA PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
12.1 EUROPE PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
12.2 EUROPE PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
12.3 EUROPE PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS TREATMENT MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
12.4 EUROPE PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS TREATMENT MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
12.5 EUROPE PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
12.6 EUROPE PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
13.1 ASIA PACIFIC PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
13.2 ASIA PACIFIC PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
13.3 ASIA PACIFIC PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS TREATMENT MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
13.4 ASIA PACIFIC PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS TREATMENT MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
13.5 ASIA PACIFIC PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
13.6 ASIA PACIFIC PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
14.1 LATIN AMERICA PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)/p>
14.2 LATIN AMERICA PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
14.3 LATIN AMERICA PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS TREATMENT MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
14.4 LATIN AMERICA PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS TREATMENT MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
14.5 LATIN AMERICA PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
14.6 LATIN AMERICA PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS TREATMENT MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS TREATMENT MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031)< (USD MILLION)/p>
16.1 F. Hoffmann-La Roche Ltd.
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Genzyme Corporation
16.3 Glialogix Inc.
16.4 Kyorin Pharmaceutical Co. Ltd.
16.5 MedDay SA
16.6 Santhera Pharmaceuticals Holding AG
16.7 Teva Pharmaceutical Industries Ltd.
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
Segment by Type- ApE
- Biotin
- GZ-402668
- Ibudilast
- Idebenone
- Laquinimod Sodium
- Others
Segment by Application
- Hospital
- Clinic
- Others
Companies
F. Hoffmann-La Roche Ltd.
Genzyme Corporation
Glialogix Inc.
Kyorin Pharmaceutical Co. Ltd.
MedDay SA
Santhera Pharmaceuticals Holding AG
Teva Pharmaceutical Industries Ltd.
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.